New York: The world's first wireless pacemaker, developed by an Indian-origin scientist, has shown promising results after one year of human trials. The device, resembling a tiny, metal silver tube and smaller than a triple-A battery, is only a few centimeters in length, making it less than ten per cent the size of a traditional pacemaker.
“This is the first time we've seen one-year follow-up data for this innovative, wireless cardiac pacing technology and our results show the leadless pacemaker is comparable to traditional pacemakers,” said Dr Vivek Reddy, Director of Arrhythmia Services at The Mount Sinai Hospital here, who is the study's co-investigator.
In comparison to a conventional pacemaker, the new-age leadless pacemaker eliminates the need for a surgical pocket and no visible pacemaker device under a patient's chest skin, no incision scar on the chest, no connector wires or leads, and no restrictions on a patient's daily activities. The device's benefits may also allow for less patient discomfort, infections, and device complications and dysfunction. “Our latest findings further support the promising performance and safety of this minimally-invasive, non-surgical pacing device. More long-term follow-up of these LEADLESS study patients will further our understanding of the potential advantages, benefits, and complication risks of leadless pacemaker technology, along with additional ongoing, larger trials,” Dr Reddy said.
The study's long-term follow-up has evaluated 32 patients with a slowed heartbeat, bradycardia at two hospitals in Prague and one in Amsterdam, the hospital said in a statement. The miniature, leadless cardiac pacemaker is placed directly inside a patient's heart without surgery during a catheter-guided procedure through the groin via the femoral vein.
It works by closely monitoring the heart's electrical rhythms and if the heart beat is too slow it provides electrical stimulation therapy to regulate it. The findings, which assessed device performance and patient outcomes through 12-months of follow-up, show pacing thresholds (0.43 volts) and sensing (10.32 mV) of the leadless pacemaker device are equivalent to those in traditional pacemakers.
Reddy presented the one-year LEADLESS study data findings during his late-breaking clinical trial presentation on May 9 at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions in San Francisco.
Reddy was the first to implant the leadless pacemaker in the United States at The Mount Sinai Hospital launching the multicenter clinical trial LEADLESS II which aims to further test the leadless pacemaker more widely for safety and efficacy in 670 patients at 50 centers across the US and Canada.
More than 4 million patients globally have a pacemaker, and 700,000 new patients receive one each year, the hospital said.